Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | MYC | P01106 | 1/20 | 0.51 |
| ▸ | MAX | P61244 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27759319 | 0.87 | MYC (0.46) | TAAR1MYCMAXTDP1L3MBTL1 | |
| SCHEMBL1478380 | 0.80 | MAPT (0.66) | L3MBTL1CHEK1LIMK1CDK5CLK4 | |
| SCHEMBL394300 | 0.78 | TAAR1 (0.76) | TAAR1TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL11724471 | 0.78 | MAPT (0.63) | MYCMAXMAPTRAB9ANPC1 | |
| SCHEMBL18072931 | 0.76 | MYC (0.66) | MYCMAXTDP1L3MBTL1CHEK1 | |
| SCHEMBL2726981 | 0.76 | MAPT (0.48) | TAAR1MYCMAXCHEK1LIMK1 | |
| SCHEMBL30487922 | 0.76 | TAAR1 (0.73) | TAAR1TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL3361349 | 0.75 | MAPT (0.64) | MAPTRAB9ANPC1TNKSPARP1 | |
| SCHEMBL6423919 | 0.73 | CA1 (0.67) | TDP1MAPTMAPK1ALDH1A1POLB | |
| SCHEMBL28198 | 0.73 | CA1 (0.67) | TDP1MAPTMAPK1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306654-A1 | MECHANOREDOX REACTION USING PIEZOELECTRIC MATERIAL, AND PRODUCTION METHOD USING SAID REACTION | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-09-29 | — | — | US | disclosed |
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-4005637-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021020362-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2021-02-04 | — | — | WO | disclosed |
| WO-2018045106-A1 | ANTI-FUNGAL TREATMENT | OHIO STATE INNOVATION FOUNDATION (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018045106-A1 | ANTI-FUNGAL TREATMENT | OHIO STATE INNOVATION FOUNDATION (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018045104-A1 | ANTI-PARASITIC COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018045104-A1 | ANTI-PARASITIC COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170306234-A1 | LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-6538004-B2 | Potassium channel modulators relax smooth muscle cells and inhibit bladder contractions; treating nervous, eating, cardiovascular, gastrointestinal, and sexual disorders | ABBOTT LABORATORIES | 2003-03-25 | — | — | US | disclosed |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARMY, UNITED STATES | 2002-10-24 | — | — | US | disclosed |
| WO-2002055025-A2 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | UNIV NORTH CAROLINA (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002036588-A2 | REVERSED AMIDINES AND METHODS OF USING FOR TREATING, PREVENTING, OR INHIBITING LEISHMANIASIS | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2002-04-18 | — | — | US | disclosed |
| US-20020007059-A1 | Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers | ABBOTT LABORATORIES | 2002-01-17 | — | — | US | disclosed |
| US-6294558-B1 | ANTIINFLAMMATORY AGENTS AND PROSTAGLANTINS | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1086097-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER INC. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064415-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-12-16 | — | — | WO | disclosed |
| US-5766556-A | SUITABLE ENVIRONMENT FOR SIMULTANEOUS SYNTHESIS OF ORGANIC COMPOUNDS, INORGANIC COMPOUNDS AND ORGANOMETALLIC COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | RCC1, CCDC47, ACIN1 | TAAR1 3806/4885MYC 4343/4885MAX 2550/4885 |
| US-20220306654-A1 | MECHANOREDOX REACTION USING PIEZOELECTRIC MATERIAL, AND PRODUCTION METHOD USING SAID REACTION | PIEZO1, PPOX, TAOK1 | TAAR1 3370/4885MYC 1991/4885MAX 1767/4885 |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGER1, PTGS1 | TAAR1 882/4885MYC 2488/4885MAX 4505/4885 |
| US-20020007059-A1 | Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers | KCNJ2, KCNH1, KCNJ1 | TAAR1 1236/4885MYC 3867/4885MAX 4868/4885 |
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | TAAR1 3764/4885MYC 4565/4885MAX 4659/4885 |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARG1, NAT1, CTSA | TAAR1 836/4885MYC 3561/4885MAX 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.